全组患者无移植相关死亡。
移植ecp处理过的脾细胞令人信服的减少了GVHD相关死亡率；这和明显减低了肝、肠道、皮肤的GVHD评分有关。
The transfer of ECP-treated splenocytes convincingly reduced GVHD-associated mortality; this was associated with significant decreases in GVHD scores in the liver, gut, and skin.
移植ecp处理过的脾细胞令人信服的减少了GVHD相关死亡率；这和明显减低了肝、肠道、皮肤的GVHD评分有关。
The transfer of ECP-treated splenocytes convincingly reduced GVHD-associated mortality; this was associated with significant decreases in GVHD scores in the liver, gut, and skin.
应用推荐